Ethyl 6-bromo-5-hydroxy-1-methyl-4-((dimethylamino)methyl)-2-[(phenylthio)methyl]-1H-indole-3-carboxylate
Arbidol
CAS: 131707-25-0
Molecular Formula: C22H25BrN2O3S
Ethyl 6-bromo-5-hydroxy-1-methyl-4-((dimethylamino)methyl)-2-[(phenylthio)methyl]-1H-indole-3-carboxylate - Names and Identifiers
Ethyl 6-bromo-5-hydroxy-1-methyl-4-((dimethylamino)methyl)-2-[(phenylthio)methyl]-1H-indole-3-carboxylate - Physico-chemical Properties
| Molecular Formula | C22H25BrN2O3S |
| Molar Mass | 477.41 |
| Density | 1.37±0.1 g/cm3(Predicted) |
| Boling Point | 591.8±50.0 °C(Predicted) |
| Flash Point | 311.7°C |
| Solubility | Chloroform (Slightly), Methanol (Slightly, Heated) |
| Vapor Presure | 1.34E-14mmHg at 25°C |
| Appearance | Solid |
| Color | Pale Brown to Light Brown |
| pKa | 6.02±0.50(Predicted) |
| Storage Condition | -20°C Freezer, Under inert atmosphere |
| Refractive Index | 1.619 |
Ethyl 6-bromo-5-hydroxy-1-methyl-4-((dimethylamino)methyl)-2-[(phenylthio)methyl]-1H-indole-3-carboxylate - Reference Information
| Overview | Abidor is a dual-effect anti-influenza virus drug developed by the former Soviet Union Pharmaceutical Chemistry Research Center, which can simultaneously fight influenza A and B viruses At the same time, it may also have antiviral activity against other respiratory virus infections. It was first listed in Russia in 1993 for the prevention and treatment of influenza and other acute respiratory virus infections. The latest research shows that Arbidol can effectively inhibit the new pneumonia coronavirus. Abidol is a non-nucleoside antiviral drug, which can specifically prevent the contact, adhesion and fusion of the influenza virus envelope and the host cell membrane by activating 2, 5-oligoadenylate synthase, thereby blocking influenza The replication of the virus can directly inhibit the synthesis of viral RNA through the nucleus. On the other hand, it has the properties of immune regulation, interference induction and antioxidant, induces host cells to produce interferon, stimulates humoral response and phagocytosis of macrophages, causes cellular immunity and humoral immunity, and its antiviral effect is closely related to improving immune function. Abidor is mainly used for the treatment and prevention of children and adults> 2 years old, and is only approved for listing in Russia and China. |
| Abidor and Darunavir can effectively inhibit the new coronavirus | On February 4, 2020, Li Lanjuan, an academician of the Chinese Academy of Engineering and a member of the high-level expert group of the National Health Commission, announced the latest research results on the treatment of pneumonia infected by the new coronavirus in Wuhan. Academician Li Lanjuan said that according to preliminary tests, in vitro cell experiments showed:(1) Abidol at a concentration of 10-30 micromoles, compared with the untreated control group, can effectively inhibit the coronavirus by 60 times, And significantly inhibit the pathological effect of the virus on cells. (2) Dalunavir can significantly inhibit virus replication at 300 micromolar concentrations. Compared with the untreated group, the inhibition efficiency reaches 280 times. Abidol is a non-nucleoside broad-spectrum antiviral drug. The main indication is influenza caused by influenza A and B influenza viruses. At the same time, it may also have antiviral activity against some other respiratory virus infections; in 2019, Abidol was included in the national medical insurance catalog for the first time and included in the list of clinically recommended drugs for antiviral influenza issued by the National Health Commission. Dalunavir is a HIV-1 protease inhibitor that selectively inhibits the cleavage of Gag-Pol multi-protein encoded by HIV in virus-infected cells, thereby preventing the formation of mature infectious virus particles. According to statistics from the State Food and Drug Administration, up to now, Abidor has a total of 5 pharmaceutical companies that have been approved, including Shi Yao Group (01093.HK)(Shi Yao Ouyi), Shi Si Yao (02005.HK), Jiangsu Wuzhong (600200.SH), Hainan Xiansheng and other companies; Dalunawei is only produced by Xi'an Janssen (Janssen Ortho, LLC), also known as Puzeri. At present, Wuhan, Beijing, Shanghai, Chongqing, Shanxi and other provinces and cities have listed Shiyao Group's Abidor Hydrochloride Tablets (Qi Xiao) as "the first batch of drug reserves for pneumonia prevention and control of new coronavirus infection". Jiangsu Wuzhong company announced on the evening of February 3 that abidor hydrochloride tablets are one of the products in the market of Wuzhong medicine, a subsidiary company. From January to September 2019, the sales revenue of Wuzhong Pharmaceutical Abidore Hydrochloride Tablets was 16.028 million yuan, accounting for the 1.06% of the listed company's operating income; in the same period in 2018, the sales revenue was 5.839 million yuan, accounting for the 0.42% of the listed company's operating income. The sales revenue of the drug accounted for a very small proportion of the operating income of the listed company. |
| dual-effect anti-influenza virus drug | arbidol is a dual-effect anti-influenza virus drug developed by the former Soviet Union Pharmaceutical Chemistry Research Center, which can simultaneously fight influenza A and B influenza viruses. At the same time, it may also have antiviral activity against other respiratory virus infections. It was first listed in Russia in 1993 for the prevention and treatment of influenza and other acute respiratory virus infections. According to different antigenicity, influenza viruses are divided into three types: A, B, and C. Due to the rapid antigenic variation of influenza virus, humans cannot obtain lasting immunity. For the treatment of influenza, most of the clinical treatment is aimed at symptoms and prevention of secondary infection, but there is a lack of etiological treatment drugs. There are three research directions at home and abroad: vaccines, interferon and antiviral chemotherapy drugs. Due to the variability of influenza virus antigens and the multiplicity of acute respiratory virus infections, it is difficult to overcome the obstacles in the development of vaccines. However, due to the source, dosage, side effects and other reasons, interferon limits its application in influenza prevention and treatment. Therefore, the development of antiviral chemotherapy drugs is an important direction for the prevention and treatment of influenza. There are only three antiviral chemotherapy drugs currently used clinically: ribavirin, amantadine and rimantadine. Among them, although ribavirin is active against influenza A and B viruses in large doses, it has teratogenic and mutagenic toxicity of nucleoside drugs, which can cause anemia and immunosuppression. However, amantadine and rimantadine are only effective for influenza A and are easy to cause toxic reactions in the central nervous system, thus reducing the clinical use value. compared with other antiviral drugs, arbidol hydrochloride has the following eight characteristics: 1. killing influenza a and B viruses at the same time. 2. Prevent virus fusion and replication. 3. Inducing interferon can obviously improve self-immunity. 4. Significantly reduce the symptoms of influenza and shorten the course of influenza. 5. Prevent the occurrence and development of late influenza syndrome. 6. Taking influenza during the epidemic period can effectively prevent influenza. 7. In vitro test, it has curative effect on SARS virus and avian influenza virus. 8. convenient oral administration, high safety and good compliance. |
| clinical application | arbidol is suitable for the prevention and treatment of influenza a, influenza B, acute viral respiratory infection and severe acute respiratory disease syndrome, including bronchitis and pneumonia in adults and children. The early use of Abidol hydrochloride after the onset of influenza can significantly shorten the duration of the disease and reduce the severity of symptoms. It can improve cough, headache, fever, chills, sweating, sore throat, muscle soreness and fatigue in patients with influenza. Symptoms have obvious effects, and are safe and suitable for clinical use. Usage and dosage: 100 mg/capsule, oral, 2 capsules each time for children over 13 years old and adults, 1 capsule each time for children aged 6-12 years old, and 50mg orally for children aged 2-6 years old. Treatment: 3 times a day, 3~5 days. Prevention: Take it once every 3 days for 3 weeks during the influenza epidemic period; take it once a day for high-risk groups in contact with patients for 2 weeks. Abidor has more than 10 years of clinical application experience in Russia, Ukraine and other countries, and has been recommended by the Russian National Pharmacopoeia Committee to adults and children as therapeutic and preventive drugs for influenza A and influenza B viruses. Leneva et al. reported that 500 children suffering from acute viral respiratory tract infections received a clinical study of Abidol. The effective rate is about 84.8%. Abidol can shorten the duration of fever, poisoning and respiratory tract inflammation, reduce symptoms, and reduce the virus The time for antigen to be released from the nasopharynx is shortened, and the clinical effect is good. In a randomized double-blind placebo-controlled clinical study to evaluate the safety and effectiveness of this product on naturally acquired influenza, Wang Mengzhao and others selected 232 cases of 18-65 years old, influenza symptoms 36 hours, and body temperature above 37.8 ℃. Among them, 125 cases of influenza virus infection were randomly divided into two groups, 59 PPi cases in the experimental group and 66 cases in the control group, taking 0.2g of this product 3 times a day for 5 days, the results showed that the disease remission rate in the experimental group was higher than that in the control group. 232 cases can be used for safety analysis, 113 cases in the experimental group and 119 cases in the control group. A total of 20 adverse events may be related to the drug, of which 7 cases (6.19%) in the experimental group and 13 cases (10.90%) in the control group. There was no significant difference between the two groups (P>0.05), indicating that the early use of this product after the onset of influenza can shorten the duration of the disease and reduce the severity of symptoms. |
| pharmacological research | arbidol is a drug for preventing and treating influenza, blocking virus replication by inhibiting the fusion of influenza virus lipid membrane and host cells. Studies have shown that this product in vitro cell culture can directly inhibit the replication of influenza A and B viruses, and in vivo animal experiments can reduce the mortality of influenza virus infected mice. This product still has interferon induction effect. |
Last Update：2024-04-09 19:05:10
![Ethyl 6-bromo-5-hydroxy-1-methyl-4-((dimethylamino)methyl)-2-[(phenylthio)methyl]-1H-indole-3-carboxylate](http://res.chembk.com/assets/str/2d/1/13/131707-25-0.png)
Supplier List
Spot supply
Product Name: Arbidol Visit Supplier Webpage Request for quotationCAS: 131707-25-0
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: Arbidol Visit Supplier Webpage Request for quotationCAS: 131707-25-0
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History
Ethyl 6-bromo-5-hydroxy-1-methyl-4-((dimethylamino)methyl)-2-[(phenylthio)methyl]-1H-indole-3-carboxylate
Isocudraniaxanthone A
350029-64-0
Isocudraniaxanthone A
350029-64-0